Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial (2001)

Peer-Reviewed Study · Sara L. Kenyon; David J. Taylor; William Tarnow-Mordi; ORACLE Collaborative Group · March 31, 2001

Sara L. Kenyon et al., 2001-03-31: ORACLE II: randomised trial of 6,295 women in spontaneous preterm labour with intact membranes, testing erythromycin and/or co-amoxiclav against placebo. No antibiotic reduced the composite neonatal outcome; the trial concluded antibiotics should not be routinely prescribed in that setting.

None of the trial antibiotics was associated with a lower rate of the composite primary outcome than placebo (erythromycin 90 [5.6%], co-amoxiclav 76 [5.0%], both antibiotics 91 [5.9%], vs placebo 78 [5.0%]).

Findings (journal p. 989)

Sara L. Kenyon et al., 2001-03-31: ORACLE II: randomised trial of 6,295 women in spontaneous preterm labour with intact membranes, testing erythromycin and/or co-amoxiclav against placebo. No antibiotic reduced the composite neonatal outcome; the trial concluded antibiotics should not be routinely prescribed in that setting. Second of the two obstetric ORACLE trials. Comparator: placebo. The 'no benefit' finding here is in neonatal infection outcomes, not stage II colorectal cancer – a likely source of the confusion behind F2. Study type: randomized trial.